Eosinophilic Esophagitis: An Update on the Latest Guidelines And Evidence for Improving Patient Outcomes
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Overview
Release Date: February 12, 2024
Expiration Date (12 months after release date): February 12, 2025
Program Description
In this immersive educational program, participants will expand their understanding of managing Eosinophilic Esophagitis (EoE) in pediatric and adult patients. This program utilizes the innovative AliveSim platform, offering real-life clinical case scenarios to work through in a low-stress environment with guidance from experts in the field of gastroenterology. Patient case scenarios created by our expert faculty will cover key EoE topics such as pathogenesis, symptoms, treatment options, and personalized care plans.
Intended Audience
This CME will target gastroenterologists, including pediatric gastroenterologists as well as nurse practitioners, physician assistants and nurse specialists in GI care who treat of patients with EoE.
Commercial Supporter
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
1. Review the pathogenesis and progression of eosinophilic esophagitis (EoE).2. Identify signs and symptoms associated with EoE and apply the latest guidelines to facilitate early diagnosis.
3. Assess the clinical risk-benefit profile of available and emerging therapies for EoE.
4. Apply current guidelines and evidence to individualize treatment plans for patients with EoE.
Physician Continuing Education
In support of improving patient care, this activity has been planned and implemented by Horizon CME. Horizon CME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
Horizon CME designates this enduring activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Conflicts of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Horizon CME must ensure balance, independence, objectivity, and scientific rigor. Prior to an activity, all faculty, authors, editors, and planning committee members participating in a Horizon CME activity are required to disclose to attendees any relevant financial interest or other relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity. Horizon CME has mitigated any conflicts of interest for this activity.
Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any continuing medical education (CME) to disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Faculty
Evan S. Dellon, MD, MPHProfessor
Dept. of Medicine, Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine
University of North Carolina at Chapel Hill Mirna Chehade, MD, MPH
Professor of Pediatrics and Medicine
Icahn School of Medicine
Mount Sinai
Mount Sinai Kravis Children’s Hospital
New York, NY
Faculty Disclosures
Horizon CME requires all planners, faculty, and other contributors to disclose any financial relationships with an ACCME defined ineligible company within the past 24 months and Horizon CME has resolved any conflicts prior to this educational activity.
- Evan S. Dellon, MD MPH discloses consulting fees with Abbott, Abbvie, Adare/Ellodi, Aimmune, Akes, Contracted Research with Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, GSK, Meritage and Other/Received funds with Allakos, Aqilion, Holo during the past 24 months.
- Mirna Chehade, MD, MPH discloses consulting fee with Regeneron, Adare/Ellodi, AstraZeneca, Sanofi, Bristol Myers Squibb, Recludix Pharma, Nexstone Immunology, Allakos, Research funding with Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Bristol Myers Squibb. Consulting fees with Shire/Takeda, Phathom but that relationship has ended and research funding with Danone but that relationship has ended all during the past 24 months.
Planners
Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Other Contributors
All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.
Instructions to Receive Credit
- Participants must review all activity information, including the pre-test, learning objectives, faculty disclosure information, simulation scenario(s) and post-activity evaluation.
- To view the first simulation scenario, launch the simulation from the link provided using a PC, Mac, Tablet, or Phone with a 4G or higher internet connection.
- Interact appropriately to satisfy each objective to unlock the next objective and view the next simulation scenario.
- The simulation will track your progress until all scenario objectives are complete.
- Exit the simulation at any time, and your progress will be saved so you can return to finish at a later time.
- As you complete each scenario (1 minimum, 3 total), you will qualify for increasing levels of CE credit (ranging from 0.5 to 1.5 credits). Click or tap "Credit" to determine your CE credit status.
Evan S. Dellon, MD, MPH, is a Professor of Medicine and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine in Chapel Hill. Dr. Dellon received his undergraduate degree from Brown University and his medical degree from Johns Hopkins School of Medicine. He completed internship and residency in Internal Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health. Dr. Dellon is currently the Director of the UNC Center for Esophageal Diseases and Swallowing (CEDAS) and has served as an Associate Editor for Clinical Gastroenterology and Hepatology. Dr. Dellon’s main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of eosinophilic esophagitis (EoE) and the eosinophilic GI diseases (EGIDs). The goal of his research is to improve the lives of patients with EoE and EGIDs by learning how to better diagnose, treat, and monitor these conditions.
Mirna Chehade, MD, MPH is Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai and Mount Sinai Kravis Children’s Hospital in New York, NY. She is a board-certified pediatric gastroenterologist. She is the founding director of the Mount Sinai Center for Eosinophilic Disorders (MSCED). The Center provides cutting-edge clinical care, research, and support for patients with eosinophilic gastrointestinal diseases and their families, including eosinophilic esophagitis (EoE) and other eosinophilic gastrointestinal disorders (EGIDs) such as eosinophilic gastritis, eosinophilic enteritis and eosinophilic colitis.
Since 2013, Dr. Chehade has been voted every year as a Castle Connolly top doctor in Pediatric Gastroenterology. In 2010, she received the Cullman Family Award in Excellence in Physician Communication. Dr. Chehade was also named as a Fellow at the American Gastroenterological Association (AGA) as well as the American Academy of Allergy, Asthma, and Immunology (AAAAI) in 2021. A prolific researcher, Dr. Chehade is involved in several ongoing studies, both publicly and privately funded: she is a site principal investigator in several studies, and site principal investigator in multiple multi-center clinical studies of EGIDs.
Copyright Statement
This CME simulation activity is licensed to Horizon CME. Copyright © 2023 Syandus Inc and Horizon CME. All rights reserved. No part of this simulation activity may be reproduced without written permission from Horizon CME and Syandus Inc.